Retatrutide Half-Life and Pharmacokinetics
A research-focused look at retatrutide (LY3437943) pharmacokinetics, its approximately 6-day half-life, and what published trial literature reports.
What is retatrutide's half-life?
Published clinical-trial pharmacology reports that retatrutide (also referenced as LY3437943) has an elimination half-life of approximately 6 days, commonly described in the literature as being in the region of 5 to 7 days. This figure is cited across the early-phase pharmacokinetic literature and is the value referenced in later obesity-trial publications when describing the compound's disposition.
A half-life of roughly 6 days means that, in the trial populations studied, it took about that long for the measured plasma concentration of the compound to fall by half after reaching peak levels. This relatively long half-life is the property that supported a once-weekly administration schedule in the published trial designs. The sections below expand on how this figure was derived and what else the literature reports about the compound's pharmacokinetics.
Note that this is an investigational research compound. The figures here are drawn from published trial pharmacology and are presented for laboratory and informational reference only.
Where the half-life figure comes from
The approximately 6-day half-life is most directly traceable to early-phase human pharmacology. A Phase 1b study in type 2 diabetes, published in 2022, reported that the pharmacokinetics of LY3437943 were dose-proportional and that its half-life was approximately 6 days. Later obesity-trial publications, including the widely cited Phase 2 report, reference this same value rather than reporting a new independent measurement.
When reading secondary summaries of retatrutide pharmacokinetics, it is worth returning to the primary trial publications. Some third-party web pages attribute the 6-day figure to the wrong study, or add clearance and accumulation numbers that are not clearly supported by the published trial data. The conservative position is to treat approximately 6 days as the reported half-life and to flag any more precise claims as uncertain unless they appear in a primary source.
- Reported half-life: approximately 6 days (literature range around 5 to 7 days).
- Primary source: early-phase (Phase 1b) human pharmacokinetic data.
- Pharmacokinetics described as dose-proportional in the reported dose range.
- Later obesity trials cite, rather than re-derive, the 6-day figure.
Why a long half-life supports once-weekly dosing
Half-life is a core pharmacokinetic parameter that describes how quickly a compound is cleared from plasma. A longer half-life means concentrations decline more slowly, so the interval between administrations in a study can be extended while still maintaining measurable exposure across that interval.
Because retatrutide's half-life sits at roughly 6 days, the published clinical trials used a once-weekly administration schedule. This is stated here only as a neutral description of how the trials were designed. It is not dosing guidance, and no administration instruction is given or implied for any reader.
A long half-life also means that plasma concentrations approach a steady state over several administrations rather than immediately, as each interval overlaps with residual compound from the previous one. This steady-state behaviour is a standard consequence of the pharmacokinetics and is described in the trial literature.
Mechanism: a triple receptor agonist
Retatrutide is described in the literature as a triple agonist, meaning the molecule is engineered to interact with three distinct receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (GCG) receptor. This distinguishes it structurally from single-receptor GLP-1 agonists and from dual GLP-1 and GIP agonists.
Structurally it is a synthetic peptide-based molecule that has been modified to extend its circulating duration. These modifications, which are common to the class, are part of why the measured half-life is long enough to support an extended administration interval. This description is biochemical and structural only and makes no claim about outcomes for any individual.
For a broader overview of the compound itself, see the general reference article below.
Absorption, distribution and elimination
Beyond the headline half-life, the pharmacokinetic literature characterises retatrutide as having dose-proportional exposure across the studied range, meaning measured plasma concentration scaled roughly in line with the amount administered. This linearity is a useful property for modelling exposure in a trial setting.
Peptide-based molecules of this type are generally understood to be metabolised through proteolytic breakdown into smaller peptide fragments and amino acids, rather than being heavily processed by the liver's cytochrome enzyme systems in the way many small-molecule drugs are. Precise distribution and clearance pathways for retatrutide specifically should be read from the primary trial pharmacology where available, and treated as approximate where they are not.
- Exposure reported as dose-proportional in the studied range.
- Long circulating duration consistent with the approximately 6-day half-life.
- Peptide-class molecules are typically broken down proteolytically.
- Steady-state exposure is reached over successive intervals, not immediately.
Regulatory status in Australia and elsewhere
As of 2026, retatrutide is an investigational compound. It is not approved by the Therapeutic Goods Administration (TGA) in Australia, and it is not an approved medicine in any jurisdiction. It remains in clinical development.
The compound is being evaluated in a programme of Phase 3 trials, reported under the TRIUMPH and related trial names. Public reporting in 2026 indicated that several of these trials had read out and that the sponsor planned a regulatory filing in the United States in 2027. A filing is not an approval, and timelines reported by secondary sources frequently differ, so the current, authoritative status should be checked against the sponsor's own releases and clinical trial registries.
Because it is not an approved therapeutic good, retatrutide supplied as a research compound is for laboratory research use only. For more on the Australian legal and regulatory picture, see the dedicated article.
How it compares with related compounds
Half-life varies across this broad class of peptide molecules, which is one reason different compounds carry different study administration intervals. Retatrutide's reported half-life of approximately 6 days sits in a similar range to some other weekly-administered peptides studied in trials, and differs markedly from short-acting research peptides that clear far more quickly.
For context on where other molecules sit, the half-life reference articles for tirzepatide and semaglutide cover compounds with their own published pharmacokinetic profiles, while shorter-acting research peptides behave very differently.
A note on anti-doping relevance
Questions sometimes arise about how peptide compounds of this class relate to anti-doping frameworks. Prohibited-substance status is determined by the relevant authorities, such as the World Anti-Doping Agency, and their published lists are updated over time. Any researcher or athlete with a specific question should consult the current official prohibited list and the relevant governing body directly rather than relying on general articles.
This article makes no determination about the anti-doping status of retatrutide and should not be read as clearance for use in any sporting context.
Frequently asked questions
What is the half-life of retatrutide?
Published clinical-trial pharmacology reports a half-life of approximately 6 days, generally described as being in the region of 5 to 7 days. This figure traces back to early-phase human pharmacokinetic data.
Why does retatrutide have such a long half-life?
It is a peptide-based molecule engineered with modifications that extend its circulating duration. These structural features are common to the class and are why its half-life is reported at roughly 6 days.
How often was retatrutide administered in trials?
The published trials used a once-weekly administration schedule, which the long half-life supports. This is stated only as a description of the trial design and is not dosing guidance.
How long does retatrutide stay in the system?
Because the reported half-life is around 6 days, measurable plasma concentrations decline over a period of weeks after the final administration. Precise clearance timelines depend on individual pharmacokinetics and should be read from primary trial data.
Is retatrutide approved in Australia?
No. As of 2026 retatrutide is an investigational compound that is not TGA-approved and is not an approved medicine in any jurisdiction. It remains in Phase 3 clinical development.
How does retatrutide work mechanistically?
It is described in the literature as a triple agonist of the GLP-1, GIP and glucagon (GCG) receptors. This is a structural and biochemical description only.
Is retatrutide's half-life similar to tirzepatide or semaglutide?
Retatrutide's approximately 6-day half-life sits in a similar range to some other weekly-administered peptides studied in trials, though each compound has its own published pharmacokinetic profile. See the respective half-life reference articles for details.
This article is general information for research buyers. All Pepology products are supplied strictly for laboratory research use only and are not for human or animal use. Every batch is independently tested by Novagen Laboratories and verifiable on a public register.